ProMIS Neurosciences (PMN) Accumulated Expenses (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Accumulated Expenses came in at $4.9 million in Q1 2026, up 118.17% YoY from $2.2 million in Q1 2025, and up 6041.59% on a QoQ basis from $79748.0 in Q4 2025.
ProMIS Neurosciences (PMN) Accumulated Expenses (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Accumulated Expenses data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Accumulated Expenses rose 118.17% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 118.17% YoY) and the FY2025 annual result came in at $79748.0, up 135.67% from the prior year.
- Accumulated Expenses grew to $4.9 million in Q1 2026, from $79748.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $7.4 million in Q3 2025 to a low of -$3.2 million in Q4 2022.
- A 5-year average of $1.1 million and a median of $680321.0 in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 3081.28% — and 2025, when it surged 4200.55%.
- Tracing PMN's Accumulated Expenses over 5 years: stood at -$3.2 million in 2022, then jumped by 116.28% to $518704.0 in 2023, then slumped by 143.1% to -$223559.0 in 2024, then soared by 135.67% to $79748.0 in 2025, then surged by 6041.59% to $4.9 million in 2026.
- The last three Accumulated Expenses figures came in at $4.9 million (Q1 2026), $79748.0 (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.42 Mn |
| Mar 31, 2026 | 4.90 Mn |
| Dec 31, 2025 | 79,748.00 |
| Sep 30, 2025 | 7.42 Mn |
| Jun 30, 2025 | 303,546.00 |
| Mar 31, 2025 | 2.24 Mn |
| Dec 31, 2024 | -223,559.00 |
| Sep 30, 2024 | 172,550.00 |
| Jun 30, 2024 | 630,925.00 |
| Mar 31, 2024 | 403,319.00 |
| Dec 31, 2023 | 518,704.00 |
| Sep 30, 2023 | 729,717.00 |
| Jun 30, 2023 | 775,852.00 |
| Mar 31, 2023 | 1.72 Mn |
| Dec 31, 2022 | -3.19 Mn |
| Sep 30, 2022 | 869,975.00 |
| Jun 30, 2022 | 986,033.00 |
| Dec 31, 2021 | 106,845.00 |